To address this issue, we used gene expression data (RNA-Seq gene counts) from TCGA breast tumors to determine if any or all of the 12 pathways described above was enriched in HER2-positive tumors from a much larger dataset. This evidence concerns the gene ERBB2 and breast neoplasm.